India gets a rare end-to-end ADC manufacturing facility as Shilpa Biologicals, a material subsidiary of Shilpa Medicare, commissioned one of the country’s few fully integrated Antibody-Drug Conjugate (ADC) manufacturing plants.
Translational Research could be the key to unlocking the next phase of growth for India's pharmaceutical sector, according to a new white paper that highlights major gaps in the country's innovation ecosystem.
India has marked a milestone in innovation, Zaynich, a drug that combats multi-drug resistant superbugs.
NPPA has launched an integrated initiative unifying both the Pharma Jan Samadhan portal and the Pharma Sahi Daam portal. The government assures the ease of access and user- friendly experience,thereby promoting the digital governance to the public.
Seasonal flu is emerging as a major public health concern in India, with experts estimating that the infection is linked to nearly 1.2 lakh deaths every year.
Cashless healthcare is set to transform the lives of thousands of workers in the national capital after the Delhi Cabinet approved a new healthcare scheme worth Rs 200 crore annually.
Future FTAs in the Indian pharma industry may look different as India pushes for a stronger pharmaceutical agenda in its trade negotiations.
India may be preparing for a major shift in its healthcare access as the government looks to accelerate medical devices manufacturing India and reduce the country's dependence on imported equipment.
Biotech innovation accelerates as Parexel launches its incubator, connecting early-stage therapeutics firms with clinical and regulatory expertise to bridge development gaps.
India’s drugmakers see limited gains from the minimum import price policy as weak demand, stockpiling, and slow buyer shifts delay the impact on domestic pharma manufacturing.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")